Advances in genetic technology are revealing the molecular basis of heart failure and cardiac hypertrophy, leading to new therapeutic targets for acquired forms of the disease.
This review summarizes emerging molecular insights and signaling pathways involved in cardiac hypertrophy and heart failure, pointing toward novel therapeutic targets.
Heart failure is a leading cause of mortality in the United States. As a result of advances in genetic technology, a molecular basis of heart failure is emerging.1,2 This review highlights the ways in which these insights are leading to new therapeutic targets in patients with acquired forms of heart failure.Morphologic Classification of Cardiac HypertrophyMyocardial hypertrophy is an early milestone during the clinical course of heart failure and an important risk factor for subsequent cardiac morbidity and mortality. In response to a variety of mechanical, hemodynamic, hormonal, and pathologic stimuli, the heart adapts to increased demands for . . .
Hunter et al. (1999) conducted a review in Heart failure and cardiac hypertrophy. Advances in genetic technology are revealing the molecular basis of heart failure and cardiac hypertrophy, leading to new therapeutic targets for acquired forms of the disease.